Journal of Neurosurgery: Spine 2026;45(5):794–803
In adults undergoing minimally invasive transforaminal lumbar interbody fusion with recombinant human bone morphogenetic protein–2 (rhBMP-2), a 48-hour course of ketorolac reduced inpatient opioid use. One-year radiographic fusion met the trial’s prespecified noninferiority criterion. The duration of treatment and the use of rhBMP-2 are important when applying these findings to a local analgesia protocol.
Study and key findings
———————-
Claus and colleagues randomized 420 adults scheduled for elective fusion of one to three levels. Both groups received multimodal analgesia, with either intravenous ketorolac (15 mg every six hours for 48 hours) or saline placebo. The per-protocol cohort included 167 patients receiving ketorolac and 188 receiving placebo. Independent neuroradiologists assessed fusion, using dynamic radiographs with CT when needed.
Mean inpatient opioid consumption was 46.1 intravenous morphine milligram equivalents with ketorolac and 68.7 with placebo, a reduction of 22.7 equivalents (95% confidence interval 12.3–33.0). Mean hospital stay was 1.91 versus 2.64 days. At one year, 364 operated levels contributed to the radiographic analysis. The lower confidence bound for the difference in solid fusion remained above the prespecified margin of minus 15 percentage points.
Interpretation and limitations
——————————
Randomization and blinding strengthen the analgesic comparison. The fusion margin still allowed some loss of efficacy, and the analysis excluded patients after randomization. Radiographic follow-up was incomplete. Fusion was evaluated by operated level, whereas opioid consumption and hospital stay were measured per patient. These distinctions matter when interpreting the precision of the estimates and discussing them with patients.
Clinical takeaway
—————–
For a service using rhBMP-2 in minimally invasive lumbar fusion, the trial supports considering a brief ketorolac course within multimodal analgesia. The opioid reduction was measurable during the admission. Applying the same conclusion to prolonged anti-inflammatory treatment, a different fusion technique or a construct without rhBMP-2 would require further evidence.

You must be logged in to post a comment.